C-GSZWOrsoBio
energy metabolism, energy homeostasis, first-in-class therapies
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-GSZW
C-GSZWC-GSZWenergy metabolism, energy homeostasis, first-in-class therapies
0-100 chain-logic scale · 15 dimensions · scored on public evidence
OrsoBio energy metabolism, energy homeostasis, first-in-class therapies
OrsoBio is developing novel approaches to treat patients with severe metabolic disorders, including obesity, diabetes, severe dyslipidemias, MASH, and more. Its therapies target fundamental pathways of energy metabolism to restore energy homeostasis and improve clinical outcomes. The company highlights a team of physicians, scientists, and biotech leaders with decades of clinical and drug development experience.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
OrsoBio — Translational · Bottom quartile. Derived deterministically from 6 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (2 programs at…
Source: Deterministic